Figure S2.
Gating strategy and results of FACS and flow cytometry after MCAO and ILC2 injection. (A) Flow cytometry gating strategies and results for blood ILC2s (Lin−CD45+CD127+ST2+KLRG1+) at day 5 after MCAO in the ILC2-transferred group (upper row) and the control group (lower row). (B) Flow cytometry gating strategies and results for blood ILC2s at day 14 after MCAO in the ILC2-transferred group (upper row) and the control group (lower row). (C) Flow cytometry gating strategies and results for brain ILC2s (Lin−CD45high CD127+ST2+KLRG1+) at day 5 after MCAO in the ILC2-transferred group (upper row) and the control group (lower row). (D) Flow cytometry gating strategies and results for brain ILC2 (Lin−CD45+ST2+KLRG1+) at day 14 after MCAO in the ILC2-transferred group (upper row) and the control group (lower row).

Gating strategy and results of FACS and flow cytometry after MCAO and ILC2 injection. (A) Flow cytometry gating strategies and results for blood ILC2s (Lin−CD45+CD127+ST2+KLRG1+) at day 5 after MCAO in the ILC2-transferred group (upper row) and the control group (lower row). (B) Flow cytometry gating strategies and results for blood ILC2s at day 14 after MCAO in the ILC2-transferred group (upper row) and the control group (lower row). (C) Flow cytometry gating strategies and results for brain ILC2s (Lin−CD45high CD127+ST2+KLRG1+) at day 5 after MCAO in the ILC2-transferred group (upper row) and the control group (lower row). (D) Flow cytometry gating strategies and results for brain ILC2 (Lin−CD45+ST2+KLRG1+) at day 14 after MCAO in the ILC2-transferred group (upper row) and the control group (lower row).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal